Invesaro

Stocks Health care CAPR

NASDAQ · Health care

Capricor Therapeutics, Inc. (CAPR)

It posted a net loss of $129.4M. In fiscal 2025 capital spending exceeded operating cash flow by $72.7M. At June 30, 2026 it held $20.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

What Capricor Therapeutics, Inc. does

Capricor Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CAPR.

Revenue and profit by year

Revenue
FY18: $1.7M $1.7M FY18FY19: $1M $1M FY19FY20: $310.3K $310.3K FY20FY21: $244.9K $244.9K FY21FY22: $2.6M $2.6M FY22FY23: $25.2M $25.2M FY23FY24: $22.3M $22.3M FY24FY25: $0 $0 FY25
Net income
FY18: -$15.2M -$15.2M FY18FY19: -$7.6M -$7.6M FY19FY20: -$13.7M -$13.7M FY20FY21: -$20M -$20M FY21FY22: -$29M -$29M FY22FY23: -$22.3M -$22.3M FY23FY24: -$40.5M -$40.5M FY24FY25: -$105M -$105M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$0-$108.1M-$105M-$2.26-$72.7M
2024$22.3M-$42.6M-$40.5M-$1.15-$41.2M
2023$25.2M-$24.1M-$22.3M-$0.83-$26.9M
2022$2.6M-$29.7M-$29M-$1.18$2.9M
2021$244.9K-$20.9M-$20M-$0.87-$18M
2020$310.3K-$13.7M-$13.7M-$0.88-$10.6M

Latest SEC filings

What Capricor Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 14, 2026
  2. August 24, 2026
  3. August 19, 2026
  4. August 14, 2026
    Quarterly report 10-Q · period to June 30, 2026
  5. August 14, 2026
  6. August 13, 2026
  7. August 7, 2026
  8. August 3, 2026
  9. July 30, 2026
  10. July 29, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on June 29, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about CAPR

What does Capricor Therapeutics, Inc. do?

Capricor Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CAPR.

Is Capricor Therapeutics, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $129.4M.

When did Capricor Therapeutics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from September 14, 2026.

Similar companies

Follow CAPR

Get an email when Capricor Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow CAPR: get an email when it files

Where the numbers come from

Financial figures are the values Capricor Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.